IFN-γ producing T cells contribute to the increase of myeloid derived suppressor cells in tumor-bearing mice after cyclophosphamide treatment

International Immunopharmacology

Volumn 12, Issue 2, 2012, Pages 425-432

  Guo, Qingming ^a   Lv, Zhangchun ^b   Fu, Qihong ^c   Jiang, Chao ^a   Liu, Yang ^a   Lai, Lihua ^a   Chen, Qingyun ^a   Shen, Jiangen ^a   Wang, Qingqing ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b First People's Hospital of Yongkang   (China)

^c HANGZHOU NORMAL UNIVERSITY   (China)

Author keywords

Cyclophosphamide; IFN ; Myeloid derived suppressor cell; T cells

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BREAST TUMOR; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; IN VITRO STUDY; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL SURVIVAL; COCULTURE TECHNIQUES; CYCLOPHOSPHAMIDE; FEMALE; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MICE, NUDE; MYELOID CELLS;

EID: 84862776571     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.12.016     Document Type: Article

References (30)

1. D.I. Gabrilovich, and S. Nagaraj Myeloid-derived suppressor cells as regulators of the immune system Nat Rev Immunol 9 2009 162 174
2. T. Condamine, and D.I. Gabrilovich Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function Trends Immunol 32 2011 19 25
3. A.C. Ochoa, A.H. Zea, C. Hernandez, and P.C. Rodriguez Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma Clin Cancer Res 13 2007 721s 726s
4. B. Almand, J.I. Clark, E. Nikitina, J. van Beynen, N.R. English, and S.C. Knight Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer J Immunol 166 2001 678 689
5. F. Ghiringhelli, N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, and C. Garrido CD4+CD25 + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative Eur J Immunol 34 2004 336 344
6. M.L. Salem, A.A. Al-Khami, S.A. El-Naggar, C.M. Diaz-Montero, Y. Chen, and D.J. Cole Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells J Immunol 184 2010 1737 1747
7. C.M. Diaz-Montero, M.L. Salem, M.I. Nishimura, E. Garrett-Mayer, D.J. Cole, and A.J. Montero Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy Cancer Immunol Immunother 58 2009 49 59
8. I. Angulo, F.G. de las Heras, J.F. Garcia-Bustos, D. Gargallo, M.A. Munoz-Fernandez, and M. Fresno Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+) CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice Blood 95 2000 212 220
9. B. Pelaez, J.A. Campillo, J.A. Lopez-Asenjo, and J.L. Subiza Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism J Immunol 166 2001 6608 6615
10. V. Bronte, and P. Zanovello Regulation of immune responses by l-arginine metabolism Nat Rev Immunol 5 2005 641 654
11. K. Movahedi, M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, and A. Beschin Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity Blood 111 2008 4233 4244
12. C. Murdoch, M. Muthana, S.B. Coffelt, and C.E. Lewis The role of myeloid cells in the promotion of tumour angiogenesis Nat Rev Cancer 8 2008 618 631
13. M.L. Salem, A.N. Kadima, S.A. El-Naggar, M.P. Rubinstein, Y. Chen, and W.E. Gillanders Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8 + T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells J Immunother 30 2007 40 53
14. L. Bracci, F. Moschella, P. Sestili, V. La Sorsa, M. Valentini, and I. Canini Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration Clin Cancer Res 13 2007 644 653
15. G. Schiavoni, F. Mattei, T. Di Pucchio, S.M. Santini, L. Bracci, and F. Belardelli Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer Blood 95 2000 2024 2030
16. E. Proietti, G. Greco, B. Garrone, S. Baccarini, C. Mauri, and M. Venditti Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice J Clin Invest 101 1998 429 441
17. H.K. Le, L. Graham, E. Cha, J.K. Morales, M.H. Manjili, and H.D. Bear Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice Int Immunopharmacol 9 2009 900 909
18. H. Li, Y. Han, Q. Guo, M. Zhang, and X. Cao Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1 J Immunol 182 2009 240 249
19. P. Liu, J. Jaffar, I. Hellstrom, and K.E. Hellstrom Administration of cyclophosphamide changes the immune profile of tumor-bearing mice J Immunother 33 2010 53 59
20. D. Berd, H.C. Maguire Jr., and M.J. Mastrangelo Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide Cancer Res 44 1984 5439 5443
21. M.L. Salem, C.M. Diaz-Montero, A.A. Al-Khami, S.A. El-Naggar, O. Naga, and A.J. Montero Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C) J Immunol 182 2009 2030 2040
22. T.S. Tzai, J.S. Lin, and N.H. Chow Modulation of antitumor immunity of tumor-bearing mice with low-dose cyclophosphamide J Surg Res 65 1996 139 144
23. M.B. Mokyr, J.C. Hengst, and S. Dray Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors Cancer Res 42 1982 974 979
24. F. Chalmin, S. Ladoire, G. Mignot, J. Vincent, M. Bruchard, and J.P. Remy-Martin Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells J Clin Invest 120 2010 457 471
25. P.C. Rodriguez, C.P. Hernandez, D. Quiceno, S.M. Dubinett, J. Zabaleta, and J.B. Ochoa Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma J Exp Med 202 2005 931 939
26. P. Cheng, C.A. Corzo, N. Luetteke, B. Yu, S. Nagaraj, and M.M. Bui Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein J Exp Med 205 2008 2235 2249
27. L. Giordanengo, N. Guinazu, C. Stempin, R. Fretes, F. Cerban, and S. Gea Cruzipain, a major Trypanosoma cruzi antigen, conditions the host immune response in favor of parasite Eur J Immunol 32 2002 1003 1011
28. O. Goni, P. Alcaide, and M. Fresno Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1(+))CD11b(+)immature myeloid suppressor cells Int Immunol 14 2002 1125 1134
29. Y. Nefedova, M. Fishman, S. Sherman, X. Wang, A.A. Beg, and D.I. Gabrilovich Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells Cancer Res 67 2007 11021 11028
30. J. Ozao-Choy, G. Ma, J. Kao, G.X. Wang, M. Meseck, and M. Sung The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies Cancer Res 69 2009 2514 2522